The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Anti‐high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats
Abstract
The high mobility group box‐1 (HMGB1), originally identified as an architectural nuclear protein, exhibits an inflammatory cytokine‐like activity in the extracellular space. Here we show that treatment with neutralizing anti‐HMGB1 monoclonal antibody (mAb; 200 μg, twice) remarkably ameliorated brain infarction induced by 2‐h occlusion of the middle cerebral artery in rats, even when the mAb was administered after the start of reperfusion. Consistent with the 90% reduction in infarct size, the accompanying neurological deficits in locomotor function were significantly improved. Anti‐HMGB1 mAb inhibited the increased permeability of the blood‐brain barrier, the activation of microglia, the expression of TNF‐α and iNOS, and suppressed the activity of MMP‐9, whereas it had little effect on blood flow. Intracerebroventricular injection of HMGB1 increased the severity of infarction. Immunohistochemi‐cal studyrevealed that HMGB1 immunoreactivityin the cell nuclei decreased or disappeared in the affected areas, suggesting the release of HMGB1 into the extracellular space. These results indicate that HMGB1 plays a critical role in the development of brain infarction through the amplification of plural inflammatory responses in the ischemic region and could be an out‐standingly suitable target for the treatment. Intravenous injection of neutralizing anti‐HMGB1 mAb provides a novel therapeutic strategy for ischemic stroke.— Liu, K., Mori, S., Takahashi, H. K., Tomono, Y., Wake, H., Kanke, T., Sato, Y., Hiraga, N., Adachi, N., Yoshino, T., Nishibori, M. Anti‐high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J . 21, 3904–3916 (2007)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., et al. (1999) · Science · doi:10.1126/science.285.5425.248 · Cited by 3,385
Bederson, J. B., Pitts, L. H., Tsuji, M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. (1986) · Stroke · doi:10.1161/01.str.17.3.472 · Cited by 2,681
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1594 · Cited by 2,487
Andersson, U., Wang, H., Palmblad, K., Aveberger, A.-C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.565 · Cited by 1,401
The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434651100 · Cited by 1,126
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion
Tsung, A., Sahai, R., Tanaka, H., Nakao, A., Fink, M. P., Lotze, M. T., Yang, H., Li, J., Tracey, K. J., Geller, D. A., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042614 · Cited by 1,113
Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W., & Rosenberg, G. A. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600375 · Cited by 1,060
Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.-C., Moskowitz, M. A., Fini, M. E., & Lo, E. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07724.2001 · Cited by 1,004
High mobility group box 1 protein interacts with multiple Toll-like receptors
Park, J. S., Gamboni-Robertson, F., He, Q., Svetkauskaite, D., Kim, J.-Y., Strassheim, D., Sohn, J.-W., Yamada, S., Maruyama, I., Banerjee, A., et al. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00401.2005 · Cited by 932
Cited by
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
DAMPening Inflammation by Modulating TLR Signalling
Piccinini, A. M., & Midwood, K. S. (2010) · Mediators of Inflammation · doi:10.1155/2010/672395 · Cited by 973
The immunology of acute stroke
Chamorro, Á., Meisel, A., Planas, A. M., Urra, X., van de Beek, D., & Veltkamp, R. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.98 · Cited by 707
A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics
Mutua, V., & Gershwin, L. J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08804-7 · Cited by 639
Targeting Inflammation Driven by HMGB1
Yang, H., Wang, H., & Andersson, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00484 · Cited by 636
Alarmins: awaiting a clinical response
Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N., & Nanchahal, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62423 · Cited by 511
Post‐ischemic brain damage: pathophysiology and role of inflammatory mediators
Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., & Corasaniti, M. T. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06766.x · Cited by 459
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
Bertheloot, D., & Latz, E. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.34 · Cited by 455
Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain
Shichita, T., Hasegawa, E., Kimura, A., Morita, R., Sakaguchi, R., Takada, I., Sekiya, T., Ooboshi, H., Kitazono, T., Yanagawa, T., et al. (2012) · Nature Medicine · doi:10.1038/nm.2749 · Cited by 452
Self-citationThe HMGB1 Receptor RAGE Mediates Ischemic Brain Damage
Muhammad, S., Barakat, W., Stoyanov, S., Murikinati, S., Yang, H., Tracey, K. J., Bendszus, M., Rossetti, G., Nawroth, P. P., Bierhaus, A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2435-08.2008 · Cited by 412
Targeting HMGB1 in inflammation
Yang, H., & Tracey, K. J. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.019 · Cited by 351
Zaiss, M., Xu, J., Goerke, S., Khan, I. S., Singer, R. J., Gore, J. C., Gochberg, D. F., & Bachert, P. (2014) · NMR in Biomedicine · doi:10.1002/nbm.3054 · Cited by 316
Zhang, J., Takahashi, H. K., Liu, K., Wake, H., Liu, R., Maruo, T., Date, I., Yoshino, T., Ohtsuka, A., Mori, S., et al. (2011) · Stroke · doi:10.1161/strokeaha.110.598334 · Cited by 314
Self-citationHMGB1 as a therapeutic target in disease
Xue, J., Suarez, J. S., Minaai, M., Li, S., Gaudino, G., Pass, H. I., Carbone, M., & Yang, H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30125 · Cited by 294
Frank, M. G., Weber, M. D., Watkins, L. R., & Maier, S. F. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.03.010 · Cited by 237
High‐mobility group box‐1 in sterile inflammation
Tsung, A., Tohme, S., & Billiar, T. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12276 · Cited by 187
Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke
Shichita, T., Ago, T., Kamouchi, M., Kitazono, T., Yoshimura, A., & Ooboshi, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07941.x · Cited by 136
Clark, I. A., & Vissel, B. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13181 · Cited by 84
Targeting HMGB1 TLR4 signaling as a novel approach to treatment of cerebral ischemia
Yang, Q.-W. (2010) · Frontiers in Bioscience · doi:10.2741/s119 · Cited by 55
Kamiya, M., Kimura, N., Umezawa, N., Hasegawa, H., & Yasuda, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1191815 · Cited by 21
Metadata
- Authors
- Liu, K., Mori, S., Takahashi, H. K., Tomono, Y., Wake, H., Kanke, T., Sato, Y., Hiraga, N., Adachi, N., Yoshino, T., & Nishibori, M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-07-12
- Volume
- 21
- Issue
- 14
- Pages
- 3904-3916
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2149240296
- Cited by
- 366
- References
- 49
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.